Hit enter to search or ESC to close
Inceptua GroupInceptua GroupInceptua GroupInceptua Group
  • About
    • History
    • Mission
    • Quality
    • Leadership
    • Careers
  • Comparator Sourcing &
    Clinical Trial Services
  • Pre-approval &
    Unlicensed Medicines Access
    • For companies seeking support for access to their medicines
    • For physicians seeking access to unlicensed medicines
  • Inceptua
    Pharma
    • Jetrea®(ocriplasmin)
    • Farydak®(panobinostat)
  • News
    • Insights
    • News and Press Releases
  • Contact
    • General contacts
    • Partnering request
    • Medicines access requests
    • Safety and product complaints
    • Inceptua Pharma Access to Medicines Policy
  • IMAP Medicines Access Portal
  • 日本語
    Category

    Press release

    FeaturedInceptua PharmaPress release

    Elevar Therapeutics Inc. Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe   

    Elevar Therapeutics Inc. Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe       December 28 2020, Elevar Therapeutics, Inc, a fully integrated biopharmaceutical company built…
    Inceptua Group
    Inceptua GroupDecember 28, 2020
    FeaturedPress release

    Inceptua Partners with Global Blood Therapeutics for an Early Access Program for Voxelotor for Patients with Sickle Cell Disease

    LUXEMBOURG, Dec. 3, 2020 Inceptua announces that the company has entered into a partnership with Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company focused on discovering, developing and delivering treatments…
    Inceptua Group
    Inceptua GroupDecember 3, 2020
    FeaturedPress release

    Inceptua receives approval of marketing authorization transfer of Jetrea® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion

    LUXEMBOURG – 25 September, 2020 – Inceptua Group  – pharmaceutical company and service partner announces that the European Commission (EC) has approved the transfer of the marketing authorisation for Jetrea®…
    Inceptua Group
    Inceptua GroupSeptember 25, 2020
    FeaturedPress release

    Inceptua Group Announces Partnership with BioCryst on Expanded Access Program for Patients with Hereditary Angioedema

    LUXEMBOURG – June 26, 2020 –Inceptua Group – pharmaceutical company and service partner spanning throughout the product lifecycle – from clinical trial comparator sourcing, packaging, labelling, and distribution solutions, through…
    Inceptua Group
    Inceptua GroupJune 26, 2020
    FeaturedPress release

    Global License Agreement a Building Block in Strategic Growth Plans

    LUXEMBOURG – 23 March, 2020 – Inceptua – pharmaceutical company and service partner - and biopharmaceutical company Oxurion have announced a global license agreement for the commercialization of JETREA®, a…
    Inceptua Group
    Inceptua GroupMarch 23, 2020
    FeaturedPress release

    Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA®

    Press release: Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA® Oxurion announces the signing of a JETREA® global license agreement with Inceptua Group. JETREA® is…
    Inceptua Group
    Inceptua GroupMarch 13, 2020
    FeaturedPress release

    Inceptua and Portola enter exclusive distribution agreement for Ondexxya®

    LUXEMBOURG / SAN FRANCISCO – 7th February  2020 –  Inceptua, a global pharmaceutical company and service partner and Portola - US developer and manufacturer of therapeutic agents focusing on thrombosis…
    Inceptua Group
    Inceptua GroupFebruary 7, 2020
    FeaturedPress release

    Inceptua appoints new Head of Asia-Pacific, Clinical Trial Services

    Inceptua has offices in both Japan and China where the regional Clinical Trial Services Team provides strategic sourcing and supply of clinical trial materials with associated clinical packaging and labelling…
    Inceptua Group
    Inceptua GroupFebruary 5, 2020
    Press release

    Inceptua and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US

    NEWTOWN, PA., and LUXEMBOURG, Dec 6, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with…
    Inceptua Group
    Inceptua GroupDecember 6, 2019
    Press release

    Inceptua appoints new President North America

    To further strengthen its position as a leading pharmaceutical company and service partner, Inceptua appoints Paul Wituschek as President North America effective 1 January, 2020. Paul will take on the…
    Inceptua Group
    Inceptua GroupDecember 5, 2019
    1 2 Next

    © 2021 Inceptua Group.
    Contact | Privacy policy | Terms of use | Cookie policy
    Anti-slavery and Human trafficking statement | Company information

    • About
      • History
      • Mission
      • Quality
      • Leadership
      • Careers
    • Comparator Sourcing &
      Clinical Trial Services
    • Pre-approval &
      Unlicensed Medicines Access
      • For companies seeking support for access to their medicines
      • For physicians seeking access to unlicensed medicines
    • Inceptua
      Pharma
      • Jetrea®(ocriplasmin)
      • Farydak®(panobinostat)
    • News
      • Insights
      • News and Press Releases
    • Contact
      • General contacts
      • Partnering request
      • Medicines access requests
      • Safety and product complaints
      • Inceptua Pharma Access to Medicines Policy
    • IMAP Medicines Access Portal
    • 日本語